Comparative studies of the granulopoietic enhancing effects of biosynthetic human insulin‐like growth factors I and II

Journal of Cellular Physiology

Volumn 157, Issue 1, 1993, Pages 178-183

  Merchav, Shoshana ^a   Lake, Mats ^b   Skottner, Anna ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Department of Pharmacology ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INSULIN LIKE GROWTH FACTOR 2; RECOMBINANT INTERLEUKIN 3; RECOMBINANT PROTEIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; GRANULOPOIESIS; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES; ANTIGEN-PRESENTING CELLS; BONE MARROW CELLS; CELL DIVISION; COMPARATIVE STUDY; GRANULOCYTES; HUMAN; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MACROPHAGES; RECEPTOR, IGF TYPE 1; STEM CELLS;

EID: 0027422232     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.1041570123     Document Type: Article

References (43)

1. Insulin‐like growth factor I (IGF‐I) and IGF‐II hormonal action in cultured rat granulosa cells: Mediation via type I but not type II receptors
2. Pure erythropoietic colony and burst formation in serum‐free culture and their enhancement by insulin‐like growth factor I
3. Mechanism of action of serum factors that regulate granulopoiesis in vitro: Possible physiologic role of serum‐inhibiting activity
4. Sequence of a cDNA clone encoding human proinsulin‐like growth factor II
5. Stimulating spectrum of human recombinant multi‐CSF (IL‐3) on human marrow precursors: Importance of accessory cells
6. The human erythrocyte insulin‐like growth factor I receptor: Characterization and demonstration of ligand‐stimulated autophosphorylation
7. Stimulation and inhibition by normal serum of colony formation in vitro by bone marrow cells
8. Insulin‐like growth factor I stimulates human erythroid colony formation in vitro
9. Quantitation of insulin‐like growth factor‐I binding to highly purified human erythroid colony‐forming units
10. Interactions of insulin, insulin‐like growth factor II and platelet‐derived growth factor in erythropoietic culture
11. Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action
12. Human recombinant granulocyte‐macrophage colony stimulating factor and interleukin 3 have overlapping but distinct hematopoietic activities
13. Specificity spillover at the hormone receptor‐ exploring its role in human disease
14. Action of the insulin‐like growth factors
15. Characterization of insulin‐like growth factor I receptors on human erythroleukemia cell line (K562 cells)
16. Growth hormone and insulin‐like growth factor I increase macrophage uptake and degradation of low‐density lipoprotein
17. Insulin‐like growth factors I and II in fetal and adult bovine serum. Purification, primary structures and immunological cross‐reactivities
18. Sequence of cDNA encoding human insulin‐like growth factor precursor
19. An antibody that blocks insulin‐like growth factor (IGF) binding to the type II receptor is neither an agonist nor an inhibitor of IGF‐stimulated biologic responses in L6 myoblasts
20. Monoclonal antibodies to receptors for insulin and somatomedin C
21. Enhancement of erythropoiesis in vitro by human growth hormone is mediated by insulin‐like growth factor I
22. Enhancement of human granulopoiesis in vitro by biosynthetic insulin‐like growth factor I/somatomedin C and human growth hormone
23. Comparative studies of the erythroid‐potentiating effects of biosynthetic human insulin‐like growth factors I and II
24. Growth of human hemopoietic colonies in response to recombinant gibbon interleukin 3: Comparison with human recombinant granulocyte and granulocyte‐macrophage colony‐stimulating factor
25. The type II insulin‐like growth factor receptor does not mediate increased DNA synthesis in H‐35 hepatoma cells
26. Separation of functionally distinct human granulocyte‐macrophage colony‐stimulating factors
27. Insulin‐like growth factor‐II (IGF‐II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF‐I receptor
28. Functional interactions between colony‐stimulating factors and the insulin family hormones myeloid leukemic cells
29. Granulocyte‐macrophage colony stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF
30. Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells
31. A triple stain technique to evaluate monocyte, neutrophil and eosinophil proliferation in soft agar cultures
32. Receptors for the insulin‐like growth factors on human erythrocytes
33. Insulin‐like growth factor (IGF)/somatomedin receptor subtypes: Structure, function and relationships to insulin receptors and IGF carrier proteins
34. Human colony‐forming units‐erythroid do not require accessory cells, but do require direct interaction with insulin‐like growth factor I and/or insulin for erythroid development
35. Effects of insulin and insulin‐like growth factor I on growth of human leukemia cells in serum‐free and protein‐free medium
36. Recombinant human granulocyte colony‐stimulating factor: Effects on normal and leukemic myeloid cells
37. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells
38. Insulin and IGF‐I binding to megakaryoblasts
39. IGF‐2 stimulated growth mediated by the type 2 receptor
40. The somatomedins: Biological actions and physiologic control mechanisms
41. Insulin‐like growth factors/somatomedins: Structure, secretion, biological actions and physiological roles
42. Binding of nonsuppressible insulin‐like activity to human serum: Evidence for a carrier protein
43. Radioimmunological detection of insulin‐like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia